Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a nasal spray soothe dry eyes? new study investigates

NCT ID NCT07606625

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a varenicline nasal spray for treating dry eye and meibomian gland dysfunction. Researchers will measure changes in tear film thickness and stability in 65 adults with mild to moderate symptoms. The goal is to see if the spray improves eye comfort and gland function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 65 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Is 18 years of age and has full legal capacity to volunteer (no max age requirement) * Baseline Ocular Surface Disease Index (OSDI) \>13 * Has mild to moderate MGD * Has best corrected visual acuity of 20/40 or better * Has had an oculo-visual examination in the last two years * Is willing to continue other daily dry eye management regimen (e.g., warm compresses, and/or eyelid margin cleaning) * Is willing to discontinue other prescription medications for dry eye disease (DED) management * Is willing to stop any topical eye drops before all planned visits * Has read, understood, and completed the informed consent letter Exclusion Criteria: * Is participating in any other type of clinical or research study * Is currently pregnant, nursing, lactating, or planning a pregnancy * Is currently having \>50% blockage of Meibomian glands in more than two eyelids or significant atrophy (i.e., severe MGD) * Is currently using any topical ocular medications * Has chronic or currently active sinus related problems * Has blepharitis \> grade 1 * Has active ocular infections * Has a condition or in a situation which, in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation in the study * Has received Rx DED treatment within one week of enrollment * Has received any thermal or light-based DED treatment within 30 days of enrollment * Has significant corneal epithelial defects * Has abnormal eyelid anatomy * Has corneal neuropathic pain * Has chronic or recurrent epistaxis (nosebleeds), coagulation disorders, or other conditions that may have led to a clinically significant increased risk of bleeding * Has any intraocular surgery including trabeculectomy (MIGS, laser, or small incision glaucoma surgery allowed), extraocular surgery in either eye within 3 months, or refractive surgery within 12 months of enrollment * Has a known allergy to a product used in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry eye syndrome Lacerations Meibomian Gland Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • U.C. Berkeley Clinical Research Center

    RECRUITING

    Berkeley, California, 94720, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.